Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.
06/22/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delay
|Common Stock CUSIP||812578 102|
|Fiscal Year||Jan. 1 - Dec. 31|